Medical Oncology, Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Caserta, Campania, Italy.
Medical Oncology, Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Caserta, Campania, Italy.
ESMO Open. 2020 Sep;4(Suppl 2):e000711. doi: 10.1136/esmoopen-2020-000711.
Squamous cell carcinoma of the anus (SCCA) is a rising health issue, strongly related to other relevant medical conditions such as (HIV) and human papillomavirus (HPV) infection. Correct assessment of patients with SCCA requires a multidisciplinary evaluation and adequate follow-up. Accurate local and systemic staging, as well as risk evaluation, are essential to optimal treatment planning. Early stage tumours can be definitively treated with a combination of chemotherapy and radiotherapy, while salvage surgery is usually reserved for patients who develop local recurrence. Distant recurrence and de novo metastatic disease are associated with poorer prognosis and require palliative systemic chemotherapy, with different single agent and combination options available. Finally, recent discoveries on the carcinogenesis of SCCA have allowed the development of innovative treatment options, the most promising being immune checkpoint inhibitors. The limited systemic treatments for SCCA and low incidence of the disease, together with insufficient data from clinical research could explain the poor outcomes of these patients, which should therefore be managed in high volume centres and enrolled in clinical trials whenever possible. This article summarises the main strategies for treating patients with SCCA.
肛门鳞状细胞癌 (SCCA) 是一个日益严重的健康问题,与其他相关医疗状况密切相关,如 (HIV) 和人乳头瘤病毒 (HPV) 感染。正确评估 SCCA 患者需要多学科评估和充分的随访。准确的局部和全身分期以及风险评估对于最佳治疗计划至关重要。早期肿瘤可以通过化疗和放疗的联合治疗来明确治疗,而挽救性手术通常仅适用于发生局部复发的患者。远处复发和新发性转移性疾病与预后较差相关,需要姑息性全身化疗,有不同的单药和联合治疗方案可供选择。最后,SCCA 发生的最新发现允许开发创新的治疗方案,最有前途的是免疫检查点抑制剂。SCCA 的有限系统治疗和低发病率,加上临床研究的数据不足,可以解释这些患者的不良结局,因此应在大容量中心管理这些患者,并尽可能纳入临床试验。本文总结了治疗 SCCA 患者的主要策略。